Meeting
2019 ASCO Annual Meeting
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
Authors
Julia Chen
Kinghorn Cancer Centre, Sydney, NSW, Australia
Julia Chen , Anthony M. Joshua , Samuel R. Denmeade , Emmanuel S. Antonarakis , Megan Crumbaker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03522064
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5095)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5095
Abstract #
TPS5095
Poster Bd #
202b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC)—Interim analysis.
First Author: Boris Alexeev
Poster
2021 ASCO Annual Meeting
Identifying androgen receptor (AR) and genomic characteristics that define populations of patients with mHSPC who benefit from early PARP inhibition therapy with talazoparib.
First Author: Saro Kasparian
Poster
2020 ASCO Virtual Scientific Program
Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).
First Author: William Kevin Kelly
Poster
2020 Genitourinary Cancers Symposium
Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.
First Author: Zachery R. Reichert